
Kronos Bio Investor Relations Material
Latest events

Status Update
Kronos Bio

Q1 2025
8 May, 2025

Q4 2024
17 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Kronos Bio Inc
Access all reports
Kronos Bio Inc. is a U.S.-based biotechnology company focused on the discovery and development of therapies for cancer and other serious diseases. The company specializes in targeting dysregulated transcription factors and other key regulatory proteins involved in disease progression. Using its proprietary drug discovery platform, Kronos Bio aims to develop small-molecule therapies that address unmet medical needs. Its research spans early discovery through clinical development. The company is headquartered in San Mateo, California, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
KRON
Country
🇺🇸 United States